Rare bleeding disorders and advances in gene therapyLiu, Tiana; Yang, ZhigangbBlood Coagulation & Fibrinolysis: December 2019 - Volume 30 - Issue 8 - p 371–378 doi: 10.1097/MBC.0000000000000852 REVIEW ARTICLE Buy Abstract Author InformationAuthors Article MetricsMetrics Rare bleeding disorders usually begin in childhood and manifest as varying degrees of bleeding, which can be life-threatening in severe cases. With the development of gene editing technology, it is expected that hereditary coagulation factor disorders will someday be fundamentally cured by gene therapy. On account of their rarity, comprehension of these diseases is essential for the application of new treatment strategies. We have compiled the features of some newly discovered mutations of prothrombin, factor VII, and factor X in recent years. In addition, this review introduces the advances and obstacles in gene therapy. aLaboratory of Hematology, Guangdong Medical University bDepartment of Hematology and Rheumatology, Affiliated Zhanjiang Central People's Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China Correspondence to Zhigang Yang, Department of Hematology and Rheumatology, Affiliated Zhanjiang Central People's Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China. Tel: +86 759-3152128; e-mail: firstname.lastname@example.org Received 24 June, 2019 Revised 8 August, 2019 Accepted 21 August, 2019 Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.